Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial

Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial. Efficacy data were compared between...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahman, Farah, McLaughlin, Taryn, Mesquita, Pedro, Morin, Josee, Potvin, Diane, De Chantal, Marilyn, Aberg, Judith A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947601/
https://www.ncbi.nlm.nih.gov/pubmed/36845310
http://dx.doi.org/10.1017/cts.2022.515
_version_ 1784892592416096256
author Rahman, Farah
McLaughlin, Taryn
Mesquita, Pedro
Morin, Josee
Potvin, Diane
De Chantal, Marilyn
Aberg, Judith A.
author_facet Rahman, Farah
McLaughlin, Taryn
Mesquita, Pedro
Morin, Josee
Potvin, Diane
De Chantal, Marilyn
Aberg, Judith A.
author_sort Rahman, Farah
collection PubMed
description Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial. Efficacy data were compared between individuals with and without dorsocervical fat, stratified by tesamorelin response. Among tesamorelin responders, VAT and waist circumference (WC) decreased in both dorsocervical fat groups and did not statistically differ (VAT P = 0.657, WC P = 0.093). These data demonstrate that tesamorelin is equally effective and should be considered in the treatment of excess VAT regardless of the presence of dorsocervical fat.
format Online
Article
Text
id pubmed-9947601
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-99476012023-02-24 Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial Rahman, Farah McLaughlin, Taryn Mesquita, Pedro Morin, Josee Potvin, Diane De Chantal, Marilyn Aberg, Judith A. J Clin Transl Sci Brief Report Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial. Efficacy data were compared between individuals with and without dorsocervical fat, stratified by tesamorelin response. Among tesamorelin responders, VAT and waist circumference (WC) decreased in both dorsocervical fat groups and did not statistically differ (VAT P = 0.657, WC P = 0.093). These data demonstrate that tesamorelin is equally effective and should be considered in the treatment of excess VAT regardless of the presence of dorsocervical fat. Cambridge University Press 2022-12-07 /pmc/articles/PMC9947601/ /pubmed/36845310 http://dx.doi.org/10.1017/cts.2022.515 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
spellingShingle Brief Report
Rahman, Farah
McLaughlin, Taryn
Mesquita, Pedro
Morin, Josee
Potvin, Diane
De Chantal, Marilyn
Aberg, Judith A.
Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial
title Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial
title_full Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial
title_fullStr Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial
title_full_unstemmed Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial
title_short Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial
title_sort effect of tesamorelin in people with hiv with and without dorsocervical fat: post hoc analysis of phase iii double-blind placebo-controlled trial
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947601/
https://www.ncbi.nlm.nih.gov/pubmed/36845310
http://dx.doi.org/10.1017/cts.2022.515
work_keys_str_mv AT rahmanfarah effectoftesamorelininpeoplewithhivwithandwithoutdorsocervicalfatposthocanalysisofphaseiiidoubleblindplacebocontrolledtrial
AT mclaughlintaryn effectoftesamorelininpeoplewithhivwithandwithoutdorsocervicalfatposthocanalysisofphaseiiidoubleblindplacebocontrolledtrial
AT mesquitapedro effectoftesamorelininpeoplewithhivwithandwithoutdorsocervicalfatposthocanalysisofphaseiiidoubleblindplacebocontrolledtrial
AT morinjosee effectoftesamorelininpeoplewithhivwithandwithoutdorsocervicalfatposthocanalysisofphaseiiidoubleblindplacebocontrolledtrial
AT potvindiane effectoftesamorelininpeoplewithhivwithandwithoutdorsocervicalfatposthocanalysisofphaseiiidoubleblindplacebocontrolledtrial
AT dechantalmarilyn effectoftesamorelininpeoplewithhivwithandwithoutdorsocervicalfatposthocanalysisofphaseiiidoubleblindplacebocontrolledtrial
AT abergjuditha effectoftesamorelininpeoplewithhivwithandwithoutdorsocervicalfatposthocanalysisofphaseiiidoubleblindplacebocontrolledtrial

Ejemplares similares